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Lipoprotein (a) (Lp(a)) is a complex of low density lipoprotein (LDL) with apolipoprotein (apo) (a). To examine the size distribution of Lp(a). 
plasma was separated by fast flow gel filtration and Lp(a):B complexes were determmed in the eluate by enzyme immunoassays, in which detection 
was performed with monoclonal antibodies specific for apoB. Lp(a):B particles displayed apparent molecular masses (M,) of 2 x 10h to at least 
10 x 106. Lp(a) size isoforms differed by the expression of apoB epitopes and their interaction with cultured human skin fibroblasts. LDL was more 
effective in inhibiting bmding, uptake, and degradation of low M, Lp(a) than of high M, Lp(a). In contrast, Glu-plasminogen. a?-macroglobulin 
and tissue-type plasminogen activator were more effective in competing for the cellular degradation of high M, Lp(a) than of low M, Lp(a). Ligand 
blotting revealed that Lp(a) bound to the low density hpoprotein receptor. the low density lipoprotem receptor-related protein/a,-macroglobulin 
receptor (LRP) and to two other endosomal membrane proteins. We propose that the LDL receptor preferentially internalizes low A4, Lp(a), 
whereas LRP may have a role in the clearance of high A4, Lp(a). 
Lipoprotein (a); Apolipoprotein B; Low density lipoprotein receptor related protein; Plasminogen: c+Macroglobulin; Tissue type plasminogen 
activator; Human skin fibroblast 
1. INTRODUCTION 
The protein moiety of lipoprotein (a) (Lp(a)) is com- 
posed of apolipoprotein (apo) B-100 and ape(a) [1,2]. 
Lp(a) is a strong independent predictor for athero- 
sclerosis [3]. Ape(a) is homologous to plasminogen [4]. 
This has put forth the hypothesis that Lp(a) exerts 
thrombogenic effects by inhibiting fibrinolysis [5]. 
Plasma levels of Lp(a) are largely determined by the 
rate of synthesis [6]. The plasma half life of Lp(a) is 
similar to that of LDL [6]. Reports coping with the role 
of the LDL receptor in Lp(a) clearance are conflicting. 
Evidence that Lp(a) can specifically bind to the LDL 
receptor comes from studies with cultured cells [2,7-lo] 
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and with partially purified receptors [l 11. Most investi- 
gators, however, agree that the LDL receptor binds 
Lp(a) with significantly lower affinity than LDL, [8, 91, 
ape(a) presumably ‘masking’ the apoB- 100 receptor 
binding domain [2,10]. Maartmann-Moe et al. claimed 
that the cellular uptake of Lp(a) is entirely LDL recep- 
tor-independent [ 121. In humans, up-regulation of LDL 
receptors by cholestyramine [13] or HMG-CoA reduc- 
tase inhibitors [14] does not reduce Lp(a). 
These findings prompted us to test whether Lp(a) is 
taken up into cells by sites other than the LDL receptor. 
Previously, we have noticed that Lp(a) is heterogeneous 
with respect to particle size [15], and immunochemical 
data suggested that Lp(a) size isoforms differed by the 
expression of the receptor binding domain of apoB-100. 
Hence, we also addressed the question whether large 
and small Lp(a) molecules were targeted to different 
sites of endocytosis. In the course of our work we ob- 
tained evidence that a substantial proportion of large 
Lp(a) particles is internalized by LDL receptor-inde- 
pendent routes also involving the LDL receptor-related 
protein (LRP), a multifunctional cell surface receptor 
[ 161, which has been implicated in the clearance of chy- 
lomicron remnants [ 171 and protease-inhibitor com- 
plexes [18-221. In contrast, small Lp(a) particles were 
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preferentially targeted to the classical LDL receptor 
pathway. 
2. MATERIALS AND METHODS 
2 1. Gel pernteution chromatography I GPC) 
40 ~1 fastmg plasma (I ,552 g/l EDTA KZ, 20.000 KIE/I aprotinm) 
were loaded onto a 300 mm column of Superose 6 (Pharmacia) and 
eluted with 200 mM NaCI, 100 mM Na,HPO,, pH 7.4. at a Bow rate 
of 0.3 rnl.rnn-‘. 
Polycional anti-ape(a) (Immune. Vienna) was diluted 1:500 and 
coated to microwell plates m 0.2 M sodium carbonate, pH 10.6. Wells 
were blocked with gelatin (10 g/l) m carbonate buffer for 1 h. and 
washed twice with 200 ~1 PBS (140 mM NaCI. 2.7 mM KCl. 10 mM 
Na:HPO,. 1.5 mM KH?PO,, pH 7.4) containing 0.05% (v/v) Tween 
20 GPC column fractions (100 ~1) were apphed to the wells and 
Incubated for 2 h. The sohd phase was washed three times wtth PBS/ 
Tween 20. Lp(a):B complexes were detected with apoB specific mono- 
clonal antibodies MB3. MB19, and MB47 [23-261, followed by bioti- 
nylated anti-mouse IgG (1:8000), an avidin:biotmylated peroxidase 
complex (l:lOOO) (Vector Laboratories, Burhngame. CA), and o- 
phenylenediamme as substrate Neither plasmmogen nor LDL reacted 
in this assay 
2 3. Preparulion of Lp(ui size isoforms 
Lp(a) was purified from the regenerate fluid of a dextran sulfate 
column based LDL-apheresis system (Kanegafuchi MA 01 Lipo- 
sorber LA 15). The regenerate fluid was concentrated by tangential 
flow filtration and ultracentrifuged. first at a density of 1.125 kg/l, then 
at 1 050 kg/l The Lp(a) containing fraction was chromatographed on 
Biogel A-15m (200400 mesh, equihbrated with 50 mM Tris-I-ICI. pH 
7 4,200 mM NaCI, 10 mg/l EDTA.Na,, 20.000 KIU/I aprotinm, 1 mg/l 
NaN,. column length 100 cm) The leading and the traihng part of the 
Lp(a) peak were considered high molecular mass (HM,) and low 
molecular mass (LM,) Lp(a), respectively. Both Lp(a) subfractions 
were free of LDL as determined by agarose gel electrophoresis [27] and 
intermediate gel immunoelectrophorests [38]. HM,-Lp(a) and LM,- 
Lp(a) were iodmated as described [29] 
2.4. Binding. uptuke and degrudution of Lpia) 
Normal human skin fibroblasts were grown m 24-well polystyrene 
plates m RPM1 1640 medium supplemented with 10% (v/v) fetal calf 
serum and used at 75% confluence. Binding. uptake (binding plus 
internalization), and degradation were measured as described [30]. 
n,-Macroglobulin (a,M. Sigma) was activated with methylamine ac- 
cording to Ashcom et al. [31]. Recombinant tissue-type plasmmogen 
activator (tPA, Thomae) was inactivated with 2 mM phenylmethylsul- 
fonyl fluoride. LDL were prepared by preparative ultracentrtfugation 
(1.019 to 1.050 kg/l). 
2.5. Ltgurtd hlotttng 
Endosomal fractions enriched for LRP were prepared as described 
[32]. 100 fig of total protein were separated on 5510% polyacrylamide 
gradient gels and blotted according to Dame1 et al. [33]. Blots were 
incubated with Lp(a) subfractions and immunostained with monoclo- 
nal anti-ape(a) (~1356. Pharmacia) and anti-mouse antibodtes conm- 
gated with alkaline phosphatase. 
3. RESULTS 
To analyse the size distribution of ape(a) containing 
particles, plasma was fractionated by size exclusion 
chromatography. Lp(a) was determined in the eluate by 
enzyme immunoassays, in which detection was carried 
out with monoclonal antibodies for apoB. Fig. 1 shows 
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Fig. 1 Size distribution of Lp(a):B complexes m plasma. A plasma 
samples from a female donor (Lp(a) 236 mg/l; ape(a) phenotype: B) 
was separated by gel permeation chromatography Lp(a):B complexes 
were measured m the eluate using enzyme lmmunoassays with apoB 
specific monoclonal antibodies, MB3 (circles), MB19 (squares), and 
MB47 (triangles) The shaded bars represent the ratios of MB47 to 
MB19 immunoreactivity Retention times of VLDL. LDL. and HDL 
are indicated by vertical arrows. 
a typical elution profile. Lp(a):B complexes eluted over 
a broad A4, range: the largest Lp(a):B particles appeared 
in the void volume, the smallest ones co-eluted with 
LDL. The apparent M, of Lp(a):B complexes ranged 
from 2 x 10’ (small LDL) to at least 10 x lo6 (VLDL). 
The profiles measured with MB3 and MB47 were virtu- 
ally identical. However, when Lp(a):B complexes were 
detected with MB1 9, maximum immunoreactivity was 
observed at higher M, than with MB3 or MB47. For 
instance, the highest concentration of Lp(a):B com- 
plexes detected with MB19 eluted after 28 min; the high- 
est concentration determined with MB3 or MB47 eluted 
after 36 min. Thus, the ratio MB47/MB19 increased as 
the size of the Lp(a):B complexes decreased. 
To elucidate the functional significance of Lp(a) size 
heterogeneity, we studied the interaction of HM,-Lp(a) 
and LM,-Lp(a) with human skin fibroblasts. As shown 
in Fig. 2, radiolabelled HM,-Lp(a) and LM,-Lp(a) did 
not differ as to total binding, uptake, and degradation. 
However, when a 20-fold excess of unlabelled LDL was 
added, uptake of LM,-Lp(a), but not of HM,-Lp(a) was 
abolished. In keeping with this. LDL competed for the 
degradation of LM,-Lp(a) to a greater extent than for 
the degradation of HM,-Lp(a). Unlike uptake and deg- 
radation, binding of Lp(a) to fibroblasts at 4°C was 
only slightly competed for by LDL, but the inhibitory 
effect of LDL on LM,-Lp(a) binding was still greater 
than on HM,-Lp(a) binding. 
We further analyzed the abilities of HM,-Lp(a) and 
LM,-Lp(a) to compete with each other. with LDL, with 
Glu-plasminogen, ar,M and tPA for degradation by 
human skin fibroblasts (Fig. 3). Unlabelled HM,-Lp(a) 
and Glu-plasminogen competed with labelled HM,- 
Lp(a) for cellular degradation. LM,-Lp(a) and LDL 
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Fig. 2. Binding, uptake, and degradation of high molecular mass 
(HM,) Lp(a) and low molecular mass (LM,) Lp(a). Normal human 
fibroblasts were grown as described in section 2. To up-regulate LDL 
receptors. cells were switched to 10% (v/v) human lipoprotein deficient 
serum 40 h before the experiment. Binding (4”(Z), uptake (37’(Y), and 
degradation (37°C) of [“51]HM,-Lp(a) and [“‘I]LM,-Lp(a) were deter- 
mined as described [30]. Lp(a)-concentrations are expressed in terms 
of cholesterol. Circles: labelled Lp(a) in the absence of LDL. Squares, 
labelled Lp(a) in the presence of excess unlabelled LDL. Each data 
point is the mean of triphcate determinations. 
were ineffective as competitors for HM,-Lp(a). Unla- 
belled LM,-Lp(a) competed with labelled LM,-Lp(a), 
whereas unlabelled HM,-Lp(a) did not. LDL effectively 
displaced LM,-Lp(a), and Glu-plasminogen had no ef- 
fect on LM,-Lp(a) degradation. Activated ol,M and in- 
activated tPA inhibited the cellular degradation of 
Lp(a) (Fig. 3). Inhibition was greater with HM,-Lp(a) 
than with LM,-Lp(a). Combinations of a,M and tPA 
had no additional effects, compared to the two competi- 
tors alone. 
On ligand blots with LRP enriched endosomal mem- 
branes Lp(a) bound to the LDL receptor, to LRP-515, 
the 515 kDa subunit [34] of LRP. and to two other 
proteins of unknown molecular identity (Fig. 4). Stain- 
ing of LRP-515 with HM,-Lp(a) appeared more intense 
than with LM,-Lp(a). 
4. DISCUSSION 
In this study, we have worked out three novel aspects 
concerning the metabolism of Lp(a): we demonstrate 
that circulating Lp(a) is heterogeneous with respect to 
size, we suggest that this heterogeneity is of physiologi- 
cal relevance, and we postulate that LRP, apart from its 
role in the clearance of chylomicron remnants [17] and 
protease-inhibitor complexes [18-221, is involved in the 
metabolism of Lp(a). 
Lp(a) has been shown 
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Ftg. 3. Inhibition of degradation of radioactively labelled high molec- 
ular mass (HM,) Lp(a) and low molecular mass (LM,) Lp(a) in fibro- 
blasts by unlabelled HM,-Lp(a), LM,-Lp(a), LDL, plasmmogen. a:- 
macroglobulin and tissue-type plasminogen activator. Top panels (a 
and b). Cells were maintained in 10% (v/v) lipoprotein deficient serum 
for 40 h. and then received labelled HM,-Lp(a) and LM,-Lp(a) (5 
pg/ml Lp(a)-cholesterol). Unlabelled HM,-Lp(a) (circles). LM,-Lp(a) 
(squares), LDL (triangles) and Glu-plasminogen (open squares) were 
used as competitors at concentrations Indicated on the abscissas. Deg- 
radation of “SI-labelled HM,-Lp(a) (a) and “51-labelled LM,-Lp(a) (b) 
were assayed by measuring the amount of trichloroacettc acid-soluble 
radioactivity in the medium [30]. Bottom panels (c and d): Identical 
conditions, except that the cells were not pre-incubated with lipopro- 
tein deficient serum. Acttvated a,-macroglobulin (circles), tissue-type 
plasminogen activator (squares) and mixtures of both (triangles) were 
added as unlabelled competitors at the indicated concentrations. c: 
degradation of “‘I-labelled HM,-Lp(a); d: degradation of “51-labelled 
LM,-Lp(a). 
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Fig. 4. Binding of Lp(a) to endosomal membrane proteins by hgand 
blotting. Endosomal membrane proteins were separated by SDS-pol- 
yacrylamide gel electrophoresis and blotted to mtrocellulose. Strips 
were probed as follows: (a) total protem stain; (b) antibodies for 
LRP-515 and the 39 kDa LRP associated protem [47]. (c) HM,-Lp(a): 
(d) LM,-Lp(a). In lanes c and d, Lp(a) was detected with the ape(a) 
specific monoclonal antlbody ~1356: no staining was obtamed when 
Lp(a) was omitted. 
tography [IO], and chromatofocusing [36]. Whereas the 
heterogeneous density distribution was attributed to the 
known ape(a) polymorphism [37], no relationship could 
be delineated between the ape(a) polymorphism and 
Lp(a) heterogeneity revealed by lysine binding [lo] or 
chromatofocusing [36]. We found that Lp(a) is hetero- 
geneous with respect to particle size, even in individuals 
expressing only one ape(a) isoform (data not shown). 
Hence, Lp(a) size heterogeneity is also independent of 
the ape(a) polymorphism. The M, of the genetically 
determined ape(a) isoforms ranges between 400,000 
and 700,000. Evidently, this difference is too small to 
account for the 2 x 10h to at least 10 x lo6 size variation 
found by gel filtration. Therefore, other causes includ- 
ing the presence of more than one ape(a) molecule per 
Lp(a) particle or the formation Lp(a)-LDL complexes 
[38] may underlie Lp(a) size heterogeneity. 
The reason for the heterogeneity notwithstanding, 
Lp(a) particles of different size differed in the expression 
of apoB-100 epitopes. Compared to the epitope for 
MB19 which is located at or near the amino-terminal 
residue 71, the apparent number of MB47 epitopes was 
high on LM,-Lp(a). The MB47 epitope consists of two 
non-linear domains including amino acid residues 
3429-3453 and 3507-3523; it is located in the vicinity 
of the apoB-100 receptor binding domain [26]. Thus, we 
hypothesized that the apoB-100 receptor binding do- 
main was more exposed on LM,-Lp(a) than on HM,- 
Lp(a). Consequently, LM,-Lp(a) should be taken up by 
the LDL receptor at a higher rate than HM,-Lp(a). 
As expected, LDL was more effective in inhibiting 
cellular uptake of LM,-Lp(a) than of HM,-Lp(a). HM,- 
Lp(a) and LM,-Lp(a) poorly competed with each other 
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for degradation, indicating that the two Lp(a) sub- 
classes used different routes of internalization. Plasmin- 
ogen competed for the degradation of HM,-Lp(a), sug- 
gesting that plasminogen binding sites [39,40] may be 
involved in Lp(a) internalization. The cellular uptake of 
HM,-Lp(a) was inhibited by methylamine-activated 
a,M and inactivated tPA. Because both are ligands for 
LRP [l g-201, this strongly suggests that LRP functions 
as a receptor for Lp(a). Consistently, Lp(a) bound to 
LRP-515, the large subunit of LRP [34], in vitro. 
In addition to the LDL receptor and LRP, two other 
endosomal proteins seem to interact with Lp(a). So far, 
nothing is known on their identity. One speculative pos- 
sibility is that they are related to plasminogen receptors 
which have been found to bind Lp(a) with high affinity 
[39,40]. However. whether or not these receptors un- 
dergo endocytosis is presently unknown. 
The precise mechanism by which Lp(a) interacts with 
LRP is not clear. Some homology exists between 
kringles 1 and 2 in tPA and the kringles in ape(a) [41]. 
It is, therefore, tempting to speculate that binding of 
Lp(a) to LRP depends on ape(a). Beyond this. endocy- 
tosis of Lp(a) may require the formation of multimeric 
complexes consisting of Lp(a), LRP and other Lp(a) 
binding proteins (e.g. plasminogen receptors or LDL 
receptors), similar to the model proposed by Herz et al. 
[22] for the uptake of urokinase-type plasminogen acti- 
vator-plasminogen activator inhibitor 1 complexes by 
LRP. 
Although these issues have to be worked out in future 
studies our data are clear with respect to the fact that 
some of the uptake and degradation of Lp(a) in cells 
does not rely on the LDL receptor and that LRP con- 
tributes to the LDL receptor-independent component. 
There are multiple lines of evidence suggesting that the 
greater part of the catabolism of Lp(a) does not proceed 
via the LDL receptor pathway: Turnover studies in rats 
failed to show a relationship between LDL receptor 
activity and Lp(a) clearance [42.43]. In a heterozygous 
patient with familial hypercholesterolemia Krempler et 
al, found that Lp(a) was metabolized faster than LDL 
[6], and Knight et al. reported that the catabolic rate of 
Lp(a) was normal in familial hypercholesterolemia [44]. 
Drugs known to stimulate LDL receptors did not lower 
Lp(a) [13,14]. In individuals heterozygous for familial 
defective apoB-100, Lp(a) contained approximately 
50% of the binding-defective apoB-100, compared to 
approximately 75% in the LDL fraction from these pa- 
tients, suggesting that the LDL receptor plays a minor 
role in Lp(a) clearance [45]. Finally, our multiple-path- 
way model for Lp(a) catabolism is easily reconciled with 
the observation that several-fold over-expression of 
LDL receptors in transgenic mice increases Lp(a) elim- 
ination [46]: Normally most Lp(a) is metabolized via 
LDL receptor independent routes, and the LDL recep- 
tor pathway becomes relevant only, when LDL receptor 
expression is extremely enhanced. 
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